We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target.
- Authors
Hung, Szu-Chun; Tarng, Der-Cherng
- Abstract
Optimal treatment algorithms for erythropoiesis-stimulating agent (ESA) and iron therapy in anemic CKD patients are lacking. Kuragano et al. evaluated hemodialysis patients over two years and report increased mortality risk and/or adverse events in those with high serum ferritin levels and high ferritin fluctuations, and an increase in adverse events in iron users. Clinical practice should avoid disproportionately high ESA or iron doses to achieve hemoglobin targets, particularly in those with significant comorbidity or ESA resistance.
- Subjects
THERAPEUTIC use of iron; ERYTHROPOIESIS; CHRONIC kidney failure; HEMODIALYSIS; HEMOGLOBINS
- Publication
Kidney International, 2014, Vol 86, Issue 4, p676
- ISSN
0085-2538
- Publication type
Article
- DOI
10.1038/ki.2014.179